Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» obesity
obesity
On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs
Endpoints
Tue, 10/12/21 - 11:43 pm
Sciwind Biosciences
funding
obesity
Novo Nordisk
Altimmune slips after posting 12-week data from Phase 1 trial for weight loss therapy
Seeking Alpha
Tue, 09/28/21 - 11:14 pm
Altimmune
clinical trials
obesity
pemvidutide
Novo Nordisk Foundation teams up with Broad Institute, Harvard for diabetes, obesity research hub
Fierce Biotech
Wed, 09/15/21 - 10:54 am
Novo Nordisk Foundation
Broad Institute
Harvard
diabetes
obesity
R&D
Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity
MedCity News
Tue, 08/31/21 - 10:05 pm
Versanis Bio
Novartis
bimagrumab
clinical trials
funding
obesity
AstraZeneca teams up with Regeneron for obesity-busting drug pact focused on genetics
Fierce Biotech
Tue, 07/27/21 - 10:29 am
AstraZeneca
GPR75
obesity
Regeneron
Obesity Drug's Promise Now Hinges On Insurance Coverage
NPR
Tue, 07/6/21 - 10:39 am
Wegovy
obesity
insurance
Novo Nordisk
Regeneron pinpoints gene variants that protect against obesity, launches search for new drugs
Fierce Biotech
Thu, 07/1/21 - 10:38 pm
Regeneron
genetics
obesity
Combining forces in metabolic disorders
EP Vantage
Mon, 06/28/21 - 10:45 am
Altimmune
obesity
clinical trials
metabolic disorders
Lumen and Novo Nordisk link up on oral biologics for cardiometabolic disease
Pharma Letter
Wed, 06/16/21 - 11:56 am
Novo Nordisk
Lumen Bioscience
obesity
Novo Nordisk, armed with Wegovy green light, preps aggressive push to build obesity market
Fierce Pharma
Tue, 06/8/21 - 12:21 pm
Novo Nordisk
obesity
drug launches
Wegovy
semaglutide
Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light
Fierce Pharma
Sat, 06/5/21 - 02:26 pm
Novo Nordisk
semaglutide
obesity
FDA
Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says
Fierce Pharma
Wed, 05/5/21 - 11:09 am
Novo Nordisk
Ozempic
drug launches
obesity
Novo Nordisk to launch PhIII obesity trial for oral semaglutide
Endpoints
Wed, 04/21/21 - 11:17 pm
Novo Nordisk
diabetes
obesity
semaglutide
oral semaglutide
clinical trials
Boehringer Ingelheim, Gubra to validate new Peptides for obesity
Pharmaceutical Business Review
Tue, 03/2/21 - 10:47 am
Boehringer Ingelheim
Gubra
peptides
obesity
Novo Nordisk's blockbuster diabetes drug blows the doors off in obesity, proving highly effective in driving weight loss
Endpoints
Thu, 02/11/21 - 10:43 am
Novo Nordisk
semaglutide
obesity
Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications
Endpoints
Tue, 01/26/21 - 11:19 am
Rhythm Pharmaceuticals
clinical trials
setmelanotide
obesity
Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many
Endpoints
Tue, 12/22/20 - 10:54 am
Rhythm Pharmaceuticals
setmelanotide
obesity
clinical trials
FDA gives Rhythm the green light for setmelanotide, a drug aimed at reducing obesity in certain genetic disorders
Endpoints
Mon, 11/30/20 - 10:38 am
Rhythm Pharmaceuticals
setmelanotide
obesity
FDA
Novo adds weight to its obesity goals
EP Vantage
Thu, 09/10/20 - 10:17 am
Novo Nordisk
semaglutide
obesity
Highlights: 2020 Cardiometabolic Health Congress West Live Online
CP WIre
Fri, 08/21/20 - 12:10 pm
cardiometabolic health
cardiovascular disease
obesity
Pages
« first
‹ previous
…
11
12
13
14
15
16
17
18
19
…
next ›
last »